RECOMMENDED PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 232251 | Brepocitinib ( PF-06700841 ) | 1883299-62-4 | ≧98.0% | _1883299-62-4.png) |
| Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1 | ||||
| 20460 | Ro5-3335 | 30195-30-3 | ≧98.0% |  |
| Ro5-3335 is a lipophilic small molecule RUNX1 inhibitor. | ||||
| 233901 | RRX-001 | 925206-65-1 | ≧98.0% |  |
| RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor a | ||||
| 230401 | Glycerol phenylbutyrate ( HPN-100 ) | 611168-24-2 | ≧98.0% | .png) |
| Glycerol phenylbutyrate, also known as HPN-100, is under trials in the treatment of c | ||||
| 232252 | Brepocitinib Tosylate | 2140301-96-6 | ≧98.0% |  |
| Brepocitinib ( PF-06700841 ) is an orally available, selective inhibitor of non-recep | ||||
| 230403 | (R,S)-BI 1015550 | 1423719-27-0 | ≧98.0% | -BI_1015550_1423719-27-0.png) |
| BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of P | ||||
| 20508 | AZD5991 | 2143061-81-6 | ≧98.0% |  |
| AZD5991 is a potent and selective Mcl-1 inhibitor for treatment of hematologic cancer | ||||
| 20511 | PDD4091 | 1373651-41-2 | ≧98.0% |  |
| PDD4091 is a novel G6PD inhibitor. | ||||
| 20512 | BDTX-1535 | 2607829-38-7 | ≧98.0% |  |
| BDTX-1535 is a brain-penetrant and potent MasterKey inhibitor of oncogenic mutations | ||||
| 20576 | STX-721 | 2765525-82-2 | ≧98.0% |  |
| STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
| 20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | _2546091-70-5.png) |
| QN-302 is a G-quadruplex (G4)-selective transcription inhibitor. | ||||
| 20640 | FLAG-003 | 1614235-14-1 | ≧98.0% |  |
| FLAG-003 is a multi-acting, water-soluable small molecule therapeutic designed to tar | ||||